Total hip arthroplasty (THA) candidates have received high doses of opioids within the perioperative period for the management of surgical pain. Healthcare systems have responded by improving opioid administration documentation and are now implementing opioid-sparing protocols (OSP) into THA integrated care pathways (ICP). Here we evaluate the effectiveness of a novel OSP in primary THA at out institution. Between January 2019 to April 2019, all patients undergoing primary THA were placed under a novel OSP (Table 1). Patient demographics, inpatient/surgical factors, and inpatient opiate administration events were collected. A historical 2:1 cohort was subsequently derived from patients undergoing THA between January 2018 to August 2018. Opiate administration events collected from our EDW were converted into Morphine Milligram Equivalences (MMEs) and transformed into average MME's per patient per 24-hour interval. Nursing documented visual analog scale (VAS) pain scores were also queried and averaged per patient per 12-hour interval. To assess immediate postoperative functional status, the validated Activity Measure for Post-Acute Care (AM-PAC) Short Forms tool was utilized.Introduction
Methods
Total hip arthroplasty (THA) is extremely effective in treating debilitating arthritic conditions of the hip. With the many modular prosthetic designs available, surgeons can now precisely construct mechanical parameters such as femoral offset (FO). Although several studies have investigated relationships between offset choice and hip abductor strength, hip range of motion, and prosthetic wear rate, there is scarce data on the effect of FO on pain and functional outcomes following THA. The objective of this study was to assess the effect of restoring FO (within varying degrees compared to the contralateral non-diseased hip [CL]) on physical function, mental well-being, pain, and stiffness outcomes as measured by the Short Form 12 Health Survey (SF-12) and Western Ontario and McMaster University Osteoarthritis Index (WOMAC) at post-operative follow-up. We prospectively collected data on 249 patients that underwent unilateral THA with no or minimal disease of the contralateral hip. Baseline data collection included: age, gender, diagnosis, femoral head size, type of stem, and pre-operative SF-12 and WOMAC scores. Post-operative SF-12 and WOMAC scores were recorded during annual follow-up visits. Post-operative FO was retrospectively measured on standard anteroposterior (AP) pelvis radiographs and compared to FO of CL. FO was measured as the perpendicular distance from the femoral head center of rotation to the anatomic axis of the femur with appropriate adjustments made for image magnification. Patients were categorized into one of three groups: decreased femoral offset (dFO, less than −5 mm compared to CL), normal femoral offset (nFO, between −5 and +5 mm of CL), and increased femoral offset (iFO, greater than +5 mm compared to CL).Introduction:
Methods:
Unicompartmental knee arthroplasty (UKA) has been proven to be an effective treatment for degenerative joint disease confined to a single tibiofemoral compartment. Recently, UKAs have been performed with robotic-arm assistance (RAA) devices to build and improve upon previous computer-assisted navigation. As a pilot study, we have analyzed short term outcomes for a series of robotic-arm assisted medial UKAs and compared them to a comparable cohort of traditionally instrumented medial UKAs. Ninety-eight fixed-bearing medial UKAs were isolated in our prospective data collection database for short-term analysis for this study. Included patients completed pre and post-operative Short Form 12 version 1 Health Survey (SF12), Western Ontario and McMaster University Outcome Scores (WOMAC), and Knee Society Function Score (KSFS) questionnaires. Forty-eight RAA UKAs were performed using the MAKO RIO system with Restoris implants, and fifty manual UKAs were performed with the Zimmer® Unicompartmental High-Flex Knee System (ZUK).Introduction:
Methods:
Not all patients receive enhanced mobility and return to comfortable, independent living after Total Hip Arthroplasty (THA). It would be beneficial to both surgeons and patients to be able to predict short term outcomes for THA. The purpose of this study was to investigate factors affecting the short term outcome of primary THA and develop a multivariate regression model that can predict such outcomes. This was a prospective study of 101 patients, who underwent primary THA. All patients were followed for a minimum of 1 year. 12 independent variables, including age, gender, diagnosis, presence of preoperative comorbidities, BMI, preoperative WOMAC physical component (PC) score, type of anesthesia, type of fixation, surgical time, estimated blood loss, use of a postoperative drain, and length of stay were analyzed using correlation and multivariate regression analyses. Multivariate regression models were validated using an independent cohort. Correlation analyses showed three variables significantly influence short term THA outcome. These include preoperative WOMAC PC score (PC) (p<
0.01), gender (G) (p= 0.01) and the presence of preoperative comorbidities (CMB) (p= 0.02). By multivariate regression analysis, the following regression model was obtained: Outcome = PC*0.45 −G*9 + CMB*8 + 62. This model exhibited positive correlation (R2=.25) when compared to a separate cohort of 27 patients undergoing THA not included in the original equation derivation. Our multivariate regression analysis has yielded statistical, multivariate confirmation or non-confirmation of common, predictive THA factors that have previously been reported in the literature. This study provides a concrete, statistically significant measure indicating that preoperative WOMAC PC score, gender, and the presence of preoperative comorbidities are predictive factors for short term primary THA outcome. Finally, our multivariate regression equation can be used to predict the general short term patient outcome following primary THA.
In May 2006, the US FDA approved the first type of metal-on-metal hip resurfacing (MOMHR) for distribution in the US because of promising survivorship achieved in Europe for patients with a diagnosis of primary osteoarthritis. No long-term US survivorship data currently exists for the Birmingham Hip Resurfacing (BHR) implant. The purpose of this study was to demonstrate early efficacy with validated outcome measures and survivorship comparable to total hip arthroplasty (THA). A cohort of 79 consecutive MOMHR patients was compared to a similar cohort of 71 THA patients, controlling for age, gender and comorbidities. Mean f/u was 14.1±5 mos (range 12–24 mos). The mean age for the MOMHR group was 50±9 yrs, and mean body mass index (BMI) was 29±5. The THA group had a mean age of 52±9 yrs and a mean BMI of 30±6. Outcomes were prospectively assessed with the SF-12 and WOMAC. For both groups, pre-op pain and function scores were similar. At 1 yr f/u, MOMHR showed significantly more improvement (p<
0.05) in stiffness, pain and physical function compared to the THA. The overall complication rate was 7% in the MOMHR group and 9% in the THA group. There were no instances of displaced femoral neck fracture, component loosening, dislocation or chronic deep infection in any patient in the MOMHR cohort. These early results are promising, but longer-term follow-up is needed to properly compare MOMHR to THA which remains the current gold standard.